CD274 and cancer: Immune checkpoint inhibitors (ICIs), such as inhibitors targeting PD-1, PD-L1, and CTLA-4, are approved for the treatment of different cancer types such as melanoma, lung cancer, and head and neck squamous cell carcinoma (1–8).